Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013:2013:639391.
doi: 10.1155/2013/639391. Epub 2013 Jul 30.

The effect of ranitidine on olanzapine-induced weight gain

Fatemeh Ranjbar  1 , Alireza Ghanepour, Homayoun Sadeghi-Bazargani, Mahbob Asadlo, Amineh Alizadeh
Affiliations
Randomized Controlled Trial

The effect of ranitidine on olanzapine-induced weight gain

Fatemeh Ranjbar et al. Biomed Res Int. 2013.

Abstract

Induced weight gain is a disturbing side effect of Olanzapine that affects the quality of life in psychotic patients. The aim of this study was to assess the efficacy of Ranitidine in attenuating or preventing Olanzapine-induced weight gain. A parallel 2-arm clinical trial was done on 52 patients with schizophrenia, schizoaffective and schizophreniform disorders who received Olanzapine for the first time. All these were first-episode admitted patients. They were randomly allocated to receive either Ranitidine or placebo. The trend of body mass index (BMI) was compared between groups over 16-week course of treatment. Mean weight was 62.3 (SD: 9.6) kg at baseline. Thirty-three subjects (63.5%) had positive family history of obesity. The average BMI increment was 1.1 for Ranitidine group and 2.4 for the placebo group. The multivariate analysis showed this effect to be independent of sex, family history of obesity, and baseline BMI value. The longitudinal modeling after controlling for baseline values failed to show the whole trend slope to be different. Although the slight change in trend's slope puts forward a hypothesis that combined use of Ranitidine and Olanzapine may attenuate the weight gain long run, this needs to be retested in future larger scale long-term studies. This trial is registered with IRCT.ir 201009112181N5.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram showing the flow of participants through each stage of study to compare effect of Ranitidine with placebo on Olanzapine-induced weight gain.
Figure 2
Figure 2
BMI trends comparing placebo and ranitidine groups over the 16-week course of treatment with Olanzapine. x-axis: measurement sessions from baseline (1) to the end of 16th week (17). y-axis: mean body mass index (BMI).
See this image and copyright information in PMC

References

    1. Hosseini SH, Polonowita AK. Priapism associated with olanzapine. Pakistan Journal of Biological Sciences. 2009;12(2):198–200. - PubMed
    1. Sadock B, Sadock V. Synopsis of Psychiatry. 1st edition. Philadelphia, Pa, USA: Lippincott; 2007.
    1. Ghaffari S, Hashemi SE, Atabaki H. The national financial burden of hospitalization of diabetes in Iran. Journal of Clinical Research & Governance. 2012;1:16–21.
    1. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine: weight gain and therapeutic efficacy. Journal of Clinical Psychopharmacology. 1999;19(3):273–276. - PubMed
    1. Goff DC, Evins AE. Negative symptoms in Schizophrenia: neurobiological models and treatment response. Harvard Review of Psychiatry. 1998;6(2):59–77. - PubMed

Publication types

LinkOut - more resources